These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237 [TBL] [Abstract][Full Text] [Related]
5. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682 [TBL] [Abstract][Full Text] [Related]
6. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911 [TBL] [Abstract][Full Text] [Related]
7. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Li BH; He FP; Yang X; Chen YW; Fan JG Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593 [TBL] [Abstract][Full Text] [Related]
8. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]
9. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111 [TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis markers of nonalcoholic steatohepatitis. Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988 [TBL] [Abstract][Full Text] [Related]
11. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310 [TBL] [Abstract][Full Text] [Related]
12. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595 [TBL] [Abstract][Full Text] [Related]
13. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450 [TBL] [Abstract][Full Text] [Related]
14. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903 [TBL] [Abstract][Full Text] [Related]
15. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Brown E; Hydes T; Hamid A; Cuthbertson DJ Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271 [TBL] [Abstract][Full Text] [Related]
16. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan. Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343 [TBL] [Abstract][Full Text] [Related]
17. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743 [TBL] [Abstract][Full Text] [Related]
18. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. He W; Huang C; Zhang X; Wang D; Chen Y; Zhao Y; Li X Endocrine; 2021 Jul; 73(1):52-64. PubMed ID: 33837926 [TBL] [Abstract][Full Text] [Related]
19. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis. Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086 [TBL] [Abstract][Full Text] [Related]
20. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]